| Ident. | Authors (with country if any) | Title |
|---|
| 000199 (2015) |
K Ray Chaudhuri [Royaume-Uni] ; A. Rizos [Royaume-Uni] ; C. Trenkwalder [Allemagne] ; O. Rascol [France] ; S. Pal [Royaume-Uni] ; D. Martino [Royaume-Uni] ; C. Carroll [Royaume-Uni] ; D. Paviour [Royaume-Uni] ; C. Falup-Pecurariu [Roumanie] ; B. Kessel [Royaume-Uni] ; M. Silverdale [Royaume-Uni] ; A. Todorova [Royaume-Uni] ; A. Sauerbier [Royaume-Uni] ; P. Odin [Suède] ; A. Antonini [Italie] ; P. Martinez-Martin [Espagne] | King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation. |
| 000243 (2015) |
Joaquim J. Ferreira [Portugal] ; Anne Rosser [Royaume-Uni] ; David Craufurd [Royaume-Uni] ; Ferdinando Squitieri [Italie] ; Nicholas Mallard [États-Unis] ; Bernhard Landwehrmeyer [Allemagne] | Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. |
| 001308 (2011) |
Nicola Z. Hobbs [Royaume-Uni] ; Amy V. Pedrick [Royaume-Uni] ; Miranda J. Say [Royaume-Uni] ; Chris Frost [Royaume-Uni] ; Rachelle Dar Santos [Canada] ; Allison Coleman [Canada] ; Aaron Sturrock [Canada] ; David Craufurd [Royaume-Uni] ; Julie C. Stout [Australie] ; Blair R. Leavitt [Canada] ; Josephine Barnes [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] ; Rachael I. Scahill [Royaume-Uni] | The structural involvement of the cingulate cortex in premanifest and early Huntington's disease |
| 001363 (2011) |
Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada] | Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease |
| 001B81 (2010) |
Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Alexander Gerhard [Royaume-Uni] ; Alexander Reuss [Allemagne] ; Sylvia Reinecker [Allemagne] ; Nicole Schimke [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Friederike Sixel-Döring [Allemagne] ; Birgit Herting [Allemagne] ; Christoph Kamm [Allemagne] ; Thomas Gasser [Allemagne] ; Martin Sawires [Autriche] ; Felix Geser [Autriche] ; Martin Köllensperger [Autriche] ; Klaus Seppi [Autriche] ; Manja Kloss [Allemagne] ; Martin Krause [Allemagne] ; Christine Daniels [Allemagne] ; Günther Deuschl [Allemagne] ; Silke Böttger [Allemagne] ; Markus Naumann [Allemagne] ; Axel Lipp [Royaume-Uni] ; Doreen Gruber [Allemagne] ; Andreas Kupsch [Allemagne] ; Yansheng Du [États-Unis] ; Federico Turkheimer [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Thomas Klockgether [Allemagne] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Carmen Schade-Brittinger [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Karla Eggert [Allemagne] | Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) |
| 001C24 (2010) |
Annu Aggarwal [Inde] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Monty Silverdale [Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Coro Paisan-Ruiz [Royaume-Uni] ; Shrinivas Desai [Inde] ; Mihir Munshi [Inde] ; Darshana Sanghvi [Inde] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Mohit Bhatt [Inde] | Indian‐subcontinent NBIA: Unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms |
| 001D70 (2010) |
Pablo Arias [Espagne] ; Jamile Vivas [Espagne] ; Kenneth L. Grieve [Espagne, Royaume-Uni] ; Javier Cudeiro [Espagne] | Controlled trial on the effect of 10 days low‐frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in Parkinson's disease |
| 002050 (2009) |
Annie W. Hsu [États-Unis] ; Panida A. Piboolnurak [États-Unis] ; Alicia G. Floyd [États-Unis] ; Qiping P. Yu [États-Unis] ; James E. Wraith [Royaume-Uni] ; Marc C. Patterson [États-Unis] ; Seth L. Pullman [États-Unis] | Spiral analysis in Niemann‐Pick disease type C |
| 002099 (2009) |
Iracema Leroi [Royaume-Uni] ; Ross Overshott [Royaume-Uni] ; E. Jane Byrne [Royaume-Uni] ; Emily Daniel [Royaume-Uni] ; Alistair Burns [Royaume-Uni] | Randomized controlled trial of memantine in dementia associated with Parkinson's disease |
| 002126 (2009) |
Mahesh Odiyoor [Royaume-Uni] ; Christopher Kobylecki [Royaume-Uni] ; Richard J. Hackett [Royaume-Uni] ; Monty A. Silverdale [Royaume-Uni] ; Mark W. Kellett [Royaume-Uni] | Pramipexole and gender identity disorder: Expanding the phenotype of hypersexuality in Parkinson's disease |
| 002283 (2009) |
Christopher Kobylecki [Royaume-Uni] ; Monty A. Silverdale [Royaume-Uni] ; Anoop Varma [Royaume-Uni] ; Jeremy P. R. Dick [Royaume-Uni] ; Mark W. Kellett [Royaume-Uni] | HIV‐associated parkinsonism with levodopa‐induced dyskinesia and response to highly‐active antiretroviral therapy |
| 002564 (2008) |
Christopher Kobylecki [Royaume-Uni] ; Andrew G. Marshall [Royaume-Uni] ; Anoop Varma [Royaume-Uni] ; Mark W. Kellett [Royaume-Uni] ; Jeremy P. R. Dick [Royaume-Uni] ; Monty A. Silverdale [Royaume-Uni] | Topiramate‐responsive cerebellar axial postural tremor |
| 002571 (2008) |
Monty A. Silverdale [Canada, Royaume-Uni] ; Susanne A. Schneider [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Anthony E. Lang [Canada] | The spectrum of orolingual tremor—A proposed classification system |
| 002A40 (2008) |
Josef Priller [Allemagne] ; Daniel Ecker [Allemagne] ; Bernhard Landwehrmeyer [Allemagne] ; David Craufurd [Royaume-Uni] | A Europe‐wide assessment of current medication choices in Huntington's disease |
| 003589 (2006) |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors |
| 003700 (2005) |
Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada] | Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease |
| 003C37 (2004) |
Susan Fox [Royaume-Uni] ; Montague Silverdale [Royaume-Uni] ; Mark Kellett [Royaume-Uni] ; Rhys Davies [Royaume-Uni] ; Malcolm Steiger [Royaume-Uni] ; Nicholas Fletcher [Royaume-Uni] ; Alan Crossman [Royaume-Uni] ; Jonathan Brotchie [Royaume-Uni, Canada] | Non‐subtype‐selective opioid receptor antagonism in treatment of levodopa‐induced motor complications in Parkinson's disease |
| 004024 (2003) |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimée [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset |
| 004075 (2003) |
Peter Hagell [Suède] ; Diane Whalley [Royaume-Uni] ; Stephen P. Mckenna [Royaume-Uni] ; Olle Lindvall [Suède] | Health status measurement in Parkinson's disease: Validity of the PDQ‐39 and Nottingham Health Profile |
| 004085 (2003) |
Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] | Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease |
| 004107 (2003) |
Gregorio Segovia [Royaume-Uni, Espagne] ; Francisco Mora [Espagne] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high‐dose levodopa in the reserpine‐treated rat model of Parkinson's disease |
